Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma

NCT01738594 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT01738594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01738594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Terminated
Start date
March 22, 2013
Completion date
October 11, 2016
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent mycosis fungoides/sezary syndrome, stage i cutaneous t-cell non-hodgkin lymphoma, stage ia mycosis fungoides/sezary syndrome, stage ib mycosis fungoides/sezary syndrome, stage ii cutaneous t-cell non-hodgkin lymphoma, stage iia mycosis fungoides/sezary syndrome, stage iib mycosis fungoides/sezary syndrome, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iiia mycosis fungoides/sezary syndrome, stage iiib mycosis fungoides/sezary syndrome, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iva mycosis fungoides/sezary syndrome, stage ivb mycosis fungoides/sezary syndrome